Navigation Links
NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
Date:9/10/2009

EMERYVILLE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

NovaBay's partner in the impetigo trial is Galderma, S.A. the world's leading dermatology company. NovaBay also is currently engaged in clinical studies of NVC-422 for viral conjunctivitis with its other major partner Alcon (NYSE: ACL), the world's leading eye care company.

This double blind, randomized, sequential group study will evaluate the safety and efficacy of a dermal formulation of NVC-422 in 120 patients ages 2 to 12 at two experienced clinical centers in the Dominican Republic. Over 15 patients have been enrolled so far and final results are expected in the first half of 2010.

Impetigo is one of the most common bacterial skin infections affecting over one million people in the US alone, primarily infants and children between the ages of two and six.(1) Impetigo usually starts with direct bacterial invasion of healthy skin or when bacteria enter a break in the skin, such as a cut, scratch or insect bite. Symptoms begin with red or pimple-like sores surrounded by red skin. These sores usually occur on the face, arms and legs and fill with pus, then break open after a few days and form a thick crust. Impetigo can spread by contact w
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
2. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
3. Alcon Commences Phase 2 Clinical Trial of NovaBays NVC-422 for Viral Conjunctivitis
4. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
5. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
8. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
11. Premier Micronutrient Launches Supplement for Hearing Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Tobago , July 25, 2014  The ... & Tobago Ministry of Health approved the introduction ... significantly increases the cure rate from Hepatitis C, ... the genotype 1 virus. Telaprevir is available in ... brand INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... 2014  AMETEK, Inc. (NYSE: AME ) ... as Vice President and General Manager, Engineered Medical ... Division. "I am pleased that Kurt has ... development experience, especially in the medical device industry, and ... continued growth and success of our medical components businesses," ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... 26, 2012 /PRNewswire-iReach/ -- ShelfX, provider ... the availability of the Vending Fridge. As the ... use a simple QR code scanner from their ... seamlessly purchase refrigerated products. The Vending Fridge can ...
... 26, 2012 Upsher-Smith Laboratories, Inc. ( http://www.upsher-smith.com ... pharmacokinetic (PK) profile of USL255, its once-daily, extended-release ... Annual American Academy of Neurology (AAN) Meeting.  One ... and equal doses of immediate-release (IR) topiramate at ...
Cached Medicine Technology:ShelfX Releases A Fridge That Knows What You Took 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 3Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 4Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 5
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... Wa (PRWEB) July 28, 2014 According to ... this is a comprehensive guide that will help people get ... to readers all the necessary information about heartburn and acid ... the truth about heartburn , and risk factors for reflux ... book will help people get rid of symptoms of reflux ...
(Date:7/28/2014)... Shore Points Capital announced today that ... Loftware, Inc., through a recapitalization of the Company led ... lead investor in Loftware for over nine years, a ... international provider of enterprise level software solutions for supply ... investment for us, and we are proud of everything ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... The first systematic analysis of hepatitis E virus (HEV) ... 3000 donors in England have HEV in their plasma. ... that around 1200 HEV-containing blood components (eg, red cells, ... transfused every year in England. , The study ... south east England between Oct, 2012 and Sept, 2013 ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... ... speaker, from standing on top of the world and sharing her story of hope and determination. ... Bayfield, WI (PRWEB) April 7, 2010 ... for this year,s attempt to climb the world,s highest peak. Last year,s successful climbers whose ...
... ... to Win an Appearance on National Television—or Win an Apple iPad™ in the “Best Seller ... ... lead to TODAY’S publishing of Gerry Czarnecki’s latest book… Lead with Love. This is ...
... An analysis by Mount Sinai researchers of over eight years ... that the relationship between high consumption of fruits and vegetables ... as commonly thought. The study is published online April 6, ... . It is widely believed that a diet rich ...
... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
... , TUESDAY, April 6 (HealthDay News) -- The use of ... the past six years, even though these operations are ... more effective, a study finds. , "It was a bit ... said Dr. Richard A. Deyo, professor of family medicine and ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 2Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 3Health News:Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer 2Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Complex Spinal Operations Soar Despite Drawbacks 2Health News:Complex Spinal Operations Soar Despite Drawbacks 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: